Financial Performance (Q1 2023) - Core product and service revenue increased by 18% to $24319 thousand compared to $23888 thousand in Q1 2022 [46] - Total Proteomics revenue increased by 123% to $152 million in Q1 2023 compared to $135 million in Q1 2022 [36] - Genomics revenues decreased by 120% to $91 million in Q1 2023 compared to $104 million in Q1 2022 [36] - GAAP product and service margin was 466% in Q1 2023, a 567 basis point increase from 409% in Q4 2022 [28] - Non-GAAP product and service margin was 609% in Q1 2023, a 792 basis point increase from 529% in Q4 2022 [28] - GAAP operating expenses decreased by 11% to $287 million in Q1 2023 compared to $323 million in Q4 2022 [28] - Non-GAAP operating expenses decreased by 16% to $254 million in Q1 2023 compared to $301 million in Q4 2022 [28] - Net cash used in operating activities decreased by 56% to $85 million in Q1 2023 compared to $192 million in Q4 2022 [28] Strategic Focus - The company received a $250 million capital infusion from Casdin Capital and Viking Global [9] - The company is focused on improving operating discipline and strategic M&A [11] - The company is using the Standard BioTools Business System (SBS) to improve operations and commercial execution [23] Product and Market Highlights - Standard BioTools introduced the Hyperion XTi Imaging System [12]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _____________________________________________ Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name o ...

Forward-Looking Statements operating results. Management uses non-GAAP measures to compare the company's performance relative to forecasts and strategic plans and to benchmark the company's performance externally against competitors. The time and amount of certain material items needed to estimate non-GAAP financial measures are inherently unpredictable or outside of our control. Material changes to any of these items could have a significant effect on guidance and future GAAP results. Non-GAAP information ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________ Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name of registrant as specified in its charte ...

Standard BioTools Inc. (NASDAQ:LAB) Q4 2022 Earnings Conference Call February 14, 2023 5:00 PM ET Company Participants Peter DeNardo - IR Michael Egholm - CEO and President Vikram Jog - CFO Conference Call Participants Operator Hello, and welcome to the Standard BioTools Inc. Fourth Quarter and Full Year 2022 Financial Results Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter DeNardo, Investor Relations. Thank you. Mr. DeNardo, you may beg ...

(1) Other revenue includes development, grant and license revenue Standard BioTools Reconciliation of GAAP to Non-GAAP Net Loss ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP NET LOSS | --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------|-------|---------------------------------------------------|-------|----------------|-------|-------------------------------------------------------|-------|-----------------| | $0 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _____________________________________________ Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact na ...

Standard BioTools Inc. (NASDAQ:LAB) Q3 2022 Results Conference Call November 8, 2022 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Michael Egholm - Chief Executive Officer and President Vikram Jog - Chief Financial Officer Operator Hello, and welcome to the Standard BioTools Inc. Third Quarter 2022 Financial Results Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter DeNardo, Investor Relations. Thank you, Mr. DeNardo. Y ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _____________________________________________ Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name of ...

Unleashing tools to accelerate breakthroughs in human health SECOND QUARTER 2022 FINANCIAL RESULTS AUGUST 8, 2022 Standard BioTools Forward-looking statements L e g a l I n f o r m a t i o n This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding operational and strategic plans, revenue growth and business transformation expectations, potential acquisi ...